REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
27/10/2025
Voltar para busca
Dado oficial do USPTO
LUOXIN PHARMACEUTICAL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
39
Atualização mais recente
28/10/2025
Tipo de marca
Mista
Classes Nice
5
Data de depósito
18/07/2019
Data de registro
27/10/2020
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/10/2020
Última transação
28/10/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
Shandong, CN
Examinador
LAVACHE,LINDA M
Unidade examinadora
L60
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a design comprising two intersecting curved bands with horizontal stripes that form a Y-shaped figure. Above this design is an eight-pointed star. Two non-Latin characters appear, respectively, on the left and right of the bottom of the design. To the right of the foregoing elements are four non-Latin characters in horizontal arrangement above the wording "LUOXIN PHARMACEUTICAL" in stylized lettering.
Titulares e representantes
Titulares
SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
Representantes
Yue (Robert) Xu Apex Attorneys at Law, LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; pharmaceutical preparations for peripheral nervous system; medicinal tea; Chinese medicine nostrum in the nature of natural remedy preparations for the treatment of cardiovascular diseasehypertensionAlzheimer diseasedepressioncancerdiabeteslung diseaseliver diseasecerebral ischemiaprostate diseaseinfertilityrheumatoid arthritisimmune system diseasegastrointestinal disease; medicinal herbs; biochemical medicines for the treatment of pneumoniaurinary tract infectiongynecological infectionsskin and skin structure infectionsmeningitissepticemiacancerdiabetesprostate diseaseinfertilityrheumatoid arthritisimmune system diseasegastrointestinal disease; biochemical drugs for treatment of gastrointestinal diseases; antiseptics; dental lacquer; diapers for pets; medicinal alcohol; medicinal oils; amino acids for medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
39 publicações encontradas
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
07/03/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
09/02/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
09/02/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
27/01/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
27/10/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/08/2020
PUBO
PUBLISHED FOR OPPOSITION
11/08/2020
GPNX
NOTIFICATION PROCESSED BY IB
07/08/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/07/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
22/07/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/07/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/07/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
08/07/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/07/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
08/07/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/06/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/06/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/06/2020
RFNT
REFUSAL PROCESSED BY IB
27/03/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
20/02/2020
GNRT
NON-FINAL ACTION E-MAILED
20/02/2020
CNRT
NON-FINAL ACTION WRITTEN
20/02/2020
DOCK
ASSIGNED TO EXAMINER
22/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/12/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/12/2019
ALIE
ASSIGNED TO LIE
23/12/2019
RFNT
REFUSAL PROCESSED BY IB
14/12/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/12/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
27/11/2019
RFRR
REFUSAL PROCESSED BY MPU
27/11/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/11/2019
CNRT
NON-FINAL ACTION WRITTEN
04/11/2019
DOCK
ASSIGNED TO EXAMINER
04/10/2019
MAFR
APPLICATION FILING RECEIPT MAILED
24/09/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/09/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
17/09/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/09/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LUOXIN PHARMACEUTICAL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.